Summit, The Wellcome Trust infectious news

Summit received £1.3 million ($2 million) of a £4 million ($6.4 million) award under the Wellcome Trust's Translation Award program to develop SMT 19969 through clinical proof-of-concept to treat Clostridium difficile infection. The initial payment will support a Phase I trial in healthy volunteers, which is expected to begin by year end, with data expected in 1H13. The company is eligible for the remaining £2.7 million ($4.4 million) in three success-based payments. Wellcome Trust is eligible for undisclosed royalties. SMT 19969 is a heterocyclic small molecule oral antibiotic. ...